查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750802

個人化癌症疫苗市場規模、佔有率、趨勢分析報告：按類型、技術、分銷管道、地區、細分市場預測，2025-2030 年

Personalized Cancer Vaccine Market Size, Share & Trends Analysis Report By Type (Dendritic Cell, RNA-based (mRNA), Neoantigen-based), By Technology (Cell-based, mRNA PCV), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 195 Pages | 商品交期: 2-10個工作天內

價格

個性化癌症疫苗市場的成長和趨勢

根據Grand View Research, Inc.的最新報告，全球個人化癌症疫苗市場規模預計到2030年將達到14.5億美元，2025年至2030年期間的複合年成長率為44.86%。

免疫療法、基因組學和 mRNA 技術的融合正在推動市場成長。與傳統疫苗不同，這些個人化療法針對由特定基因突變產生的新抗原，並根據每位患者獨特的腫瘤特徵進行客製化。這種精確性正在為腫瘤學治療開闢新的視野，特別是對於難治性癌症。市場成長受到生物技術投資增加、全球癌症發生率上升以及次世代定序儀的進步的推動。從臨床試驗到監管指定的快速進展，例如 Moderna 獲得的歐洲藥品管理局 PRIME 指定和默克公司 2023 年 4 月獲得的 mRNA-4157/V940 指定，都體現了這一勢頭。這些疫苗不再是推測性的治療方法，而是正在成為未來腫瘤學格局中不可或缺的一部分。

市場成長最重要的驅動力之一是基於 mRNA 的疫苗平台的創新。 COVID-19 mRNA 疫苗的成功加速了公共和私營部門對這種治療方法的信心，從而導致資金籌措增加和監管反應迅速。 Moderna 與默克公司合作開發的臨床實驗疫苗 mRNA-4157/V940 就是這項進步的一個例子。該疫苗於 2023 年 4 月獲得 EMA 的 PRIME 稱號，在 2b 期臨床試驗 (KEYNOTE-942) 中顯示出良好的結果，尤其是與默克公司的免疫療法藥物 KEYTRUDA 聯合使用時。同樣，mRNA 技術的先驅 BioNTech 在 2024 年 4 月的 AACR 年會上展示了其腫瘤學管線，重點關注基於 mRNA 的癌症疫苗和抗體-藥物偶聯物。這些創新正在為癌症治療的新時代鋪平道路，使研究人員能夠根據腫瘤序列快速生成候選疫苗，近乎即時地個人化治療，並微調免疫反應以提高療效。

提高全球對 HPV 感染、相關健康風險和疫苗接種益處的認知是推動市場成長的關鍵因素。公共衛生宣傳活動、社群媒體推廣和學校教育計畫在改變觀念和鼓勵疫苗接種方面發揮關鍵作用。擁有強大醫療保健傳播策略的國家，如澳洲和英國， 人類乳突病毒(HPV)疫苗接種率明顯較高，這反映了持續的基於證據的提高認知工作的有效性。性別中立的疫苗通訊也提高了男性族群的接受度，特別是考慮到男性口咽癌和肛門癌的發生率不斷上升。隨著性健康恥辱感的消退和越來越多的人意識到疫苗接種的長期預防癌症益處，越來越多的人開始接種疫苗。這種提高意識的努力不僅增加了需求，而且還帶來了更早的疫苗接種、更高的遵從率和更穩定的市場成長。

監管獎勵在加速個人化癌症疫苗產業發展方面發揮關鍵作用。 EMA 的 PRIME 計劃和 FDA 的突破性療法認定等項目旨在鼓勵開發有前景的嚴重治療方法。 Moderna 和 Merck 的 mRNA-4157/V940 疫苗獲得 PRIME 認定，證明了監管機構致力於促進腫瘤學創新。該認定基於積極的中期數據，顯示高風險 III/IV 期黑色素瘤患者在同時接種該疫苗和 KEYTRUDA 治療後，術後預後得到改善。同樣，BioNTech 參加 AACR2024 等重要科學論壇並發布重要的臨床更新，凸顯了監管和科學檢驗的持續加強。此類市場發展將增強投資者信心，加快新型療法的上市時間，並為治療選擇有限的癌症患者（尤其是在輔助治療環境中）帶來希望。

個人化癌症疫苗市場報告重點

  • 按類型分類，受標靶免疫療法和個人化免疫療法需求不斷成長的推動，樹突狀細胞預計在 2024 年佔據最大的市場佔有率，達到 100%。
  • 2024年，細胞技術細分市場以100%的收益佔有率領先市場，這得益於其能夠利用人體免疫系統進行標靶化和適應性的抗腫瘤反應。此細分市場包括利用患者來源細胞（尤其是樹突狀細胞、腫瘤浸潤淋巴細胞 (TIL) 或工程化T細胞）的治療方法，以呈現腫瘤特異性抗原並刺激針對癌細胞的個人化免疫攻擊。
  • 醫院部門預計將在 2024 年佔據市場主導地位，收益佔有率為 58.87%，並在預測期內以最快的複合年成長率成長，這主要受以下幾個關鍵因素的推動：醫院是癌症診斷、治療和後續護理的主要中心。
  • 在免疫療法的進步和強大的醫療保健基礎設施的推動下，北美在全球市場佔據主導地位，2024 年的佔有率為 34.07%。這一成長是由癌症發病率的上升推動的，僅在美國，2022 年就估計會有 190 萬例新的癌症病例。
  • 全球個人化疫苗產業由 Dendreon Pharmaceuticals, LLC、Gritstone Bio、CureVac、NeoCura & Innovent、Stemirna Therapeutics、Dendreon Pharmaceuticals, LLC、Elicio Therapeutics、Evaxion BIoTech、Imugene 和 Nouscom 等主要企業夥伴關係

目錄

第1章調查方法與範圍

第2章執行摘要

3. 個人化癌症疫苗市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場趨勢與展望
  • 市場動態
    • 基因組學和免疫治療技術的進展
    • 癌症發生率上升，標靶治療需求增加
    • 加強癌症免疫治療領域的合作與投資
  • 市場限制因素分析
    • 開發和製造成本高
    • 監理和物流挑戰
    • 波特五力分析
    • PESTEL分析

第4章：個人化癌症疫苗市場：按類型估計和趨勢分析

  • 個人化癌症疫苗市場：類型變異分析
  • 按類型
  • 樹突狀細胞
  • 基於RNA（mRNA）
  • 基於新抗原
  • 腫瘤相關抗原（TAA）疫苗
  • 個人化癌症疫苗市場：技術變革分析
  • 依技術
  • 基於細胞
  • mRNA PCV
  • 其他

第5章：個人化癌症疫苗市場：按分銷管道的估計和趨勢分析

  • 個人化癌症疫苗市場：分佈波動分析
  • 按分銷管道
  • 醫院
  • 診所
  • 研究和學術機構

第6章：個人化癌症疫苗市場：區域、估計與趨勢分析

  • 2024 年及 2030 年個人化癌症疫苗市場佔有率（按地區）
  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 2018-2030年北美個人化癌症疫苗市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年歐洲個人化癌症疫苗市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030年亞太地區個人化癌症疫苗市場
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 2018-2030年拉丁美洲個人化癌症疫苗市場
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2018-2030年中東及非洲個人化癌症疫苗市場
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 戰略地圖
  • 2024年公司市場佔有率分析
  • 公司簡介
    • Dendreon Pharmaceuticals, LLC
    • Gritstone Bio
    • CureVac
    • NeoCura & Innovent
    • Stemirna Therapeutics
    • Elicio Therapeutics
    • Evaxion BIoTech
    • Imugene
    • Nouscom
Product Code: GVR-4-68040-579-5

Personalized Cancer Vaccine Market Growth & Trends:

The global personalized cancer vaccine market size is expected to reach USD 1.45 billion by 2030, registering a CAGR of 44.86% from 2025 to 2030, according to a new report by Grand View Research, Inc. The convergence of immunotherapy, genomics, and mRNA technologies drives the market growth. Unlike traditional vaccines, these personalized therapies are tailored to each patient's unique tumor profile, targeting neoantigens that arise from specific genetic mutations. This precision has opened new therapeutic horizons in oncology, especially for hard-to-treat cancers. The market growth is propelled by increasing investments in biotechnology, growing incidence of cancer worldwide, and advancements in next-generation sequencing. The rapid progression from clinical trials to regulatory designations, such as the European Medicines Agency's PRIME designation for Moderna and Merck's mRNA-4157/V940 in April 2023, is emblematic of this momentum. These vaccines are no longer speculative treatments; they are becoming integral to the future oncology landscape.

One of the most pivotal drivers of market growth is innovation in mRNA-based vaccine platforms. The success of COVID-19 mRNA vaccines accelerated public and private sector confidence in the modality, leading to increased funding and faster regulatory pathways. Moderna's investigational vaccine, mRNA-4157/V940, developed in partnership with Merck, exemplifies this progress. Granted PRIME designation by the EMA in April 2023, the vaccine showed promising results in Phase 2b trials (KEYNOTE-942), especially when paired with Merck's immunotherapy drug KEYTRUDA. Similarly, BioNTech, a pioneer in mRNA technology, showcased its oncology pipeline at the AACR Annual Meeting in April 2024, highlighting its mRNA-based cancer vaccines and antibody-drug conjugates. These innovations are allowing researchers to rapidly generate vaccine candidates based on tumor sequencing, personalize therapies in near real-time, and fine-tune immune responses to enhance efficacy, paving the way for a new era in cancer treatment.

Increased global awareness regarding HPV transmission, associated health risks, and the benefits of vaccination is a major factor driving market growth. Public health campaigns, social media outreach, and school-based education initiatives have played a pivotal role in changing perceptions and encouraging vaccine acceptance. In countries with robust healthcare communication strategies, such as Australia and the UK, HPV vaccine uptake is notably high, reflecting the impact of consistent, evidence-based awareness efforts. Gender-neutral vaccination messaging has also improved acceptance among male populations, particularly in response to the growing incidence of oropharyngeal and anal cancers in men. As stigma around sexual health diminishes and more people recognize the long-term cancer prevention benefits of vaccination, broader demographic groups are being reached. These awareness initiatives are not only increasing demand but are also leading to earlier vaccination, higher compliance rates, and more consistent market growth.

Regulatory incentives are playing a crucial role in accelerating the personalized cancer vaccine industry. Programs like the EMA's PRIME scheme or the FDA's Breakthrough Therapy designation are designed to expedite the development of promising therapies for serious conditions. Moderna and Merck's mRNA-4157/V940 vaccine receiving PRIME status is a testament to the regulators' commitment to fostering innovation in oncology. This designation was based on positive interim data suggesting that patients with high-risk stage III/IV melanoma had improved outcomes post-surgery when treated with the vaccine alongside KEYTRUDA. Similarly, BioNTech's participation in major scientific forums like AACR 2024, where it revealed significant clinical updates, underscores growing regulatory and scientific validation. These developments help boost investor confidence, shorten time-to-market for novel therapies, and offer hope for cancer patients who have limited treatment options, especially in the adjuvant setting.

Personalized Cancer Vaccine Market Report Highlights:

  • Based on type, the dendritic cell segment accounted for the largest market share of 100% in 2024, driven by increasing demand for targeted and individualized immunotherapies.
  • The cell-based technology segment led the market with a 100% revenue share in 2024, underpinned by its ability to harness the body's own immune system for targeted and adaptive anti-tumor responses. This segment includes therapies that utilize patient-derived cells, particularly dendritic cells, tumor-infiltrating lymphocytes (TILs), or engineered T-cells, to present tumor-specific antigens and stimulate a personalized immune attack against cancer cells.
  • The hospitals segment dominated the market with a revenue share of 58.87% in 2024 and is expected to grow at the fastest CAGR over the forecast period, driven by several key factors. Hospitals serve as primary centers for cancer diagnosis, treatment, and follow-up care
  • North America dominated the global market, with a share of 34.07% in 2024, driven by advancements in immunotherapy and a strong healthcare infrastructure. This growth is fueled by the increasing prevalence of cancer, with the U.S. alone reporting an estimated 1.9 million new cancer cases in 2022.
  • The global personalized vaccine industry is led by several major companies, including Dendreon Pharmaceuticals, LLC, Gritstone Bio, CureVac, NeoCura & Innovent, Stemirna Therapeutics, Dendreon Pharmaceuticals, LLC, Elicio Therapeutics, Evaxion Biotech, Imugene, and Nouscom, all of which are strengthening their worldwide presence through strategies like launching new products, forging strategic partnerships, and expanding into new geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Technology
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Personalized Cancer Vaccine Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Advances in genomic and immunotherapy technologies
    • 3.4.2. Rising cancer prevalence and demand for targeted treatments
    • 3.4.3. Collaborations and increased investment in cancer immunotherapy
  • 3.5. Market Restraint Analysis
    • 3.5.1. High development and manufacturing costs
    • 3.5.2. Regulatory and logistical challenges
    • 3.5.3. Porter's Five Forces Analysis
    • 3.5.4. PESTEL Analysis

Chapter 4. Personalized Cancer Vaccine Market: Type Estimates & Trend Analysis

  • 4.1. Personalized Cancer Vaccine Market: Type Movement Analysis
  • 4.2. Personalized Cancer Vaccine Market Estimates and Forecast, by Type
  • 4.3. Dendritic Cell
    • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4. RNA-Based (mRNA)
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Neoantigen-Based
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Tumor-Associated Antigen (TAA) Vaccines
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Personalized Cancer Vaccine Market: Technology Movement Analysis
  • 4.8. Personalized Cancer Vaccine Market Estimates and Forecast, by Technology
  • 4.9. Cell-based
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. mRNA PCV
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Personalized Cancer Vaccine Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Personalized Cancer Vaccine Market: Distribution Movement Analysis
  • 5.2. Personalized Cancer Vaccine Market Estimates and Forecast, by Distribution Channel
  • 5.3. Hospitals
    • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4. Clinics
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Research & Academic Institutes
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Personalized Cancer Vaccine Market: Regional Estimates & Trend Analysis

  • 6.1. Personalized Cancer Vaccine Market Share By Region, 2024 & 2030
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Regional Market Dashboard
  • 6.4. Global Regional Market Snapshot
  • 6.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.6. North America
    • 6.6.1. North America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.6.2. U.S.
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. U.S. Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.6.3. Canada
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Canada Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.6.4. Mexico
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Mexico Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7. Europe
    • 6.7.1. Europe Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.7.2. UK
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. UK Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.7.3. Germany
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Germany Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.7.4. France
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Competitive Scenario
      • 6.7.4.3. Regulatory Framework
      • 6.7.4.4. France Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.7.5. Italy
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Competitive Scenario
      • 6.7.5.3. Regulatory Framework
      • 6.7.5.4. Italy Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.7.6. Spain
      • 6.7.6.1. Key Country Dynamics
      • 6.7.6.2. Competitive Scenario
      • 6.7.6.3. Regulatory Framework
      • 6.7.6.4. Spain Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.7.7. Denmark
      • 6.7.7.1. Key Country Dynamics
      • 6.7.7.2. Competitive Scenario
      • 6.7.7.3. Regulatory Framework
      • 6.7.7.4. Denmark Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.7.8. Sweden
      • 6.7.8.1. Key Country Dynamics
      • 6.7.8.2. Competitive Scenario
      • 6.7.8.3. Regulatory Framework
      • 6.7.8.4. Sweden Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.7.9. Norway
      • 6.7.9.1. Key Country Dynamics
      • 6.7.9.2. Competitive Scenario
      • 6.7.9.3. Regulatory Framework
      • 6.7.9.4. Norway Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8. Asia Pacific
    • 6.8.1. Asia Pacific Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.8.2. Japan
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Competitive Scenario
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Japan Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.8.3. China
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Competitive Scenario
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. China Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.8.4. India
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Competitive Scenario
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. India Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.8.5. Australia
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Competitive Scenario
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Australia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.8.6. Thailand
      • 6.8.6.1. Key Country Dynamics
      • 6.8.6.2. Competitive Scenario
      • 6.8.6.3. Regulatory Framework
      • 6.8.6.4. Thailand Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.8.7. South Korea
      • 6.8.7.1. Key Country Dynamics
      • 6.8.7.2. Competitive Scenario
      • 6.8.7.3. Regulatory Framework
      • 6.8.7.4. South Korea Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.9. Latin America
    • 6.9.1. Latin America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.9.2. Brazil
      • 6.9.2.1. Key Country Dynamics
      • 6.9.2.2. Competitive Scenario
      • 6.9.2.3. Regulatory Framework
      • 6.9.2.4. Brazil Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.9.3. Argentina
      • 6.9.3.1. Key Country Dynamics
      • 6.9.3.2. Competitive Scenario
      • 6.9.3.3. Regulatory Framework
      • 6.9.3.4. Argentina Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10. MEA
    • 6.10.1. MEA Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.10.2. South Africa
      • 6.10.2.1. Key Country Dynamics
      • 6.10.2.2. Competitive Scenario
      • 6.10.2.3. Regulatory Framework
      • 6.10.2.4. South Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.10.3. Saudi Arabia
      • 6.10.3.1. Key Country Dynamics
      • 6.10.3.2. Competitive Scenario
      • 6.10.3.3. Regulatory Framework
      • 6.10.3.4. Saudi Arabia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.10.4. UAE
      • 6.10.4.1. Key Country Dynamics
      • 6.10.4.2. Competitive Scenario
      • 6.10.4.3. Regulatory Framework
      • 6.10.4.4. UAE Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 6.10.5. Kuwait
      • 6.10.5.1. Key Country Dynamics
      • 6.10.5.2. Competitive Scenario
      • 6.10.5.3. Regulatory Framework
      • 6.10.5.4. Kuwait Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Strategy Mapping
  • 7.4. Company Market Share Analysis, 2024
  • 7.5. Company Profiles
    • 7.5.1. Dendreon Pharmaceuticals, LLC
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Gritstone Bio
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. CureVac
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. NeoCura & Innovent
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Stemirna Therapeutics
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Elicio Therapeutics
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Evaxion Biotech
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Imugene
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Nouscom
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 3 Global Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 4 Global Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 Global Personalized Cancer Vaccine Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 9 North America Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 12 U.S. Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 15 Canada Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 17 Mexico Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 18 Mexico Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Europe Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 Europe America Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 22 Europe America Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 UK Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 24 UK Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 25 UK Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Germany Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 Germany Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 28 Germany Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 30 France Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 31 France Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 33 Italy Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 34 Italy Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 Spain Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 37 Spain Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 39 Denmark Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 40 Denmark Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Sweden Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 43 Sweden Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 45 Norway Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 46 Norway Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Japan Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 53 Japan Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 China Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 China Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 56 China Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 India Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 59 India Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Australia Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 62 Australia Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Thailand Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 65 Thailand Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 South Korea Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 South Korea Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 68 South Korea Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 Latin America Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 72 Latin America Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 74 Brazil Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 75 Brazil Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 78 Argentina Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Personalized Cancer Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Personalized Cancer Vaccine Market, by type, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 85 South Africa Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 88 audi Arabia Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 91 UAE Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Personalized Cancer Vaccine Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Personalized Cancer Vaccine Market, by Technology, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Personalized Cancer Vaccine Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Personalized Cancer Vaccine Market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Personalized cancer vaccine market: Type movement analysis
  • Fig. 15 Personalized cancer vaccine market: Type outlook and key takeaways
  • Fig. 16 Dendritic Cell market estimates and forecast, 2018 - 2030
  • Fig. 17 RNA-Based (mRNA) market estimates and forecast, 2018 - 2030
  • Fig. 18 Neoantigen-based market estimates and forecast, 2018 - 2030
  • Fig. 19 Tumor-Associated Antigen (TAA) vaccines market estimates and forecast, 2018 - 2030
  • Fig. 20 Personalized cancer vaccine market: Technology movement analysis
  • Fig. 21 Personalized cancer vaccine market: Technology outlook and key takeaways
  • Fig. 22 Cell-based market estimates and forecast, 2018 - 2030
  • Fig. 23 mRNA PCV market estimates and forecast, 2018 - 2030
  • Fig. 24 Others market estimates and forecast, 2018 - 2030
  • Fig. 25 Personalized cancer vaccine market: Distribution channel movement analysis
  • Fig. 26 Personalized cancer vaccine market: Distribution channel outlook and key takeaways
  • Fig. 27 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 28 Clinics market estimates and forecast, 2018 - 2030
  • Fig. 29 Research & academic institutes market estimates and forecast, 2018 - 2030
  • Fig. 30 Government suppliers market estimates and forecast, 2018 - 2030
  • Fig. 31 Regional outlook, 2024 & 2030
  • Fig. 32 Global Personalized Cancer Vaccine Market: Region movement analysis
  • Fig. 33 North America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 39 UK Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 40 France Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 41 Italy Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 45 Norway Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 47 Japan Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 48 China Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 49 India Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)